Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Stock Performance Snapshot
Financial Health
Cyclerion Therapeutics is generating modest revenue and cash flow, indicating stability but limited growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CYCN
Pharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: July 31, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage focus
The company’s value drivers are trial results and regulatory milestones; these can unlock value but also carry high failure risk.
Speculative upside
Successful clinical data or a partnership could materially re-rate the stock, though many development projects do not reach approval.
Watch funding closely
With a very small market cap, financing needs and potential dilution are real concerns; liquidity may be limited for retail investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
